1BT Stock Chart & Stats
€3.76
-€0.18(-4.57%)
At close: 4:00 PM EDT
€3.76
-€0.18(-4.57%)
Day’s Range― - ―
52-Week Range€1.37 - €25.65
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€22.97M
Enterprise Value€28.67
Total Cash (Recent Filing)€5.87M
Total Debt (Recent Filing)€641.00K
Price to Earnings (P/E)<0.1
Beta0.52
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)405.30
Shares Outstanding16,832,014
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€69.06Price Target Upside1736.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory And Clinical ProgressRMAT status provides enhanced FDA engagement and a potentially faster development path. Combined with an ongoing 182-patient Phase 2b trial, it improves regulatory clarity and supports Allocetra’s prospects in a large underserved market.
Low Financial LeverageVery low leverage limits fixed financing obligations and reduces balance-sheet risk while clinical programs advance. This gives Enlivex more flexibility than a highly indebted biotech, although future funding needs remain significant.
Potential Capital AccessIf approved and completed, the placement could materially extend funding for clinical development and debt repayment. The additional put option would provide further financing capacity, though execution and shareholder approval remain necessary.
Bears Say
No Commercial RevenueThe absence of marketed-product revenue leaves Enlivex dependent on clinical success, regulatory approval and future commercialization. Continued operating losses make the business model speculative and limit evidence of durable commercial traction.
Persistent Cash BurnConsistent cash burn means Enlivex must rely on equity, debt, grants or partnerships to fund research and trials. This dependence can constrain strategic flexibility and create recurring financing or dilution risk before operating cash flow improves.
Digital Asset And Financing RiskA balance sheet increasingly tied to RAIN exposes the company to crypto-market, liquidity and regulatory risks unrelated to drug development. The amended convertible note also raises potential dilution and financing-cost risk.
Enlivex News
1BT FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was €1.37 and its highest was €25.65 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is €22.97M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 248 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -€0.017 earnings per share for the quarter, the consensus estimate of -€0.017 by €0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 16,832,014 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -€0.017 in its last earnings report, expectations of -€0.017. Following the earnings report the stock price went up 2.521%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in DE:1BT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
1BT Earnings Call
Q4 2026
0:00 / 0:00
1BT Stock 12 Month Forecast
Average Price Target
€69.06
▲(1736.74% Upside)